Skip to content

Legend Biotech

US · LEGN #2374 by market cap Listed 2020
19.12 +0.40 +2.14%
Live - 5344 symbols - heartbeat 212s ago · 2026-10-08 07:58
Pre-market 19.12 0.00%
After-hours 19.20 +0.42%
Overnight 19.25 +0.68%
Market cap
3.72B
P/B
3.02
EPS
-1.62
Reader sentiment Are you bullish or bearish on LEGN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35
    Market Newswire · 2026/7/13
  • Rating change
    Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $41.42
    Market Newswire · 2026/6/26
  • RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/9/11
  • UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28
    Market Newswire · 2026/8/14
  • Rating change
    RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59
    Market Newswire · 2026/7/27
  • Rating change
    UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $49
    Market Newswire · 2026/6/5
  • Rating change
    Oppenheimer Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/6/15
  • Rating change
    A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65
    Market Newswire · 2026/8/12
  • Rating change
    RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $63
    Market Newswire · 2026/7/7
  • UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $24
    Market Newswire · 2026/10/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)
    TipRanks · 2026/8/12
  • Rating change
    Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/6/15
  • Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74
    Market Newswire · 2026/9/11
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/9/30
  • Rating change
    A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48
    Market Newswire · 2026/8/13
  • Rating change
    Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5
    Market Newswire · 2026/7/16
  • Rating change
    UBS Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $28
    Market Newswire · 2026/7/24
  • Rating change
    Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/7/14
  • Rating change
    UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $49
    Market Newswire · 2026/6/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:58:23 · For reference only, not investment advice and not tailored to your situation.